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Background: Prostate cancer is an illness with a high incidence, especially among older men.
The  choice of a treatment option among men above 75 years is, however, not clear. Radical
prostatectomy in this age group is connected with a relatively high morbidity. A further
possibility of curative treatment is radiotherapy which can be administered in the form of
external beam or in combination with high dose rate (HDR) brachytherapy.
Aim: The aim of our work was to evaluate how HDR brachytherapy is tolerated among men
older than 75 and how associated diseases can inﬂuence the tolerance to this treatment. Of
interest to us were the treatment results and mortality from other diseases.
Materials and methods: We  analyzed a sample of 20 men above 75 years old (median 77 years)
who were undergoing treatment by a combination of external radiotherapy and brachyther-
apy. Sixteen (80%) of them had prostate cancer with an intermediate and high risk of
recurrence, four had low risk prostate cancer. Most patients, 14 (70%), had less than two
comorbidities.
Results: The median observation period was 57 months. No perioperative complications were
recorded. Acute genitourinary toxicity (GU) to a maximum grade of 1–2 manifested in 60% of
cases. Acute gastrointestinal toxicity (GIT) was observed only at grade 1 and in 25% of cases.
Late GU toxicity occurred in 35% of patients, with only one showing grade 3; late GIT toxicity
was  recorded at grade 1 only in 3 patients (15%). 70% of the men lived longer than 3 years
after treatment, at present, 50% lived more than 5 years. Long-term biochemical remission
was  achieved in 18 patients (90%).
Conclusions: HDR BRT is possible and well-tolerated in older men above 75 years in goodcondition and without serious intercurrence.
Well-selected older patients with higher-risk tumours and without serious comorbidities
undoubtedly beneﬁt from radical treatment when compared with watchful waiting.
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Table 1 – Characteristics of patients and tumours.
No of pts.
PSA ≤10  6
10–20 6
>20 8
Gleason score 4–6  4
≥7 16
T stage T1c 12
T2a-b 6
T3a 2
Table 2 – The most chronic comorbidities in our group of
patients.
Comorbidities No of pts.
Hypertension 1212  reports of practical oncology a
1.  Background
Prostate cancer occurs predominantly among older men, most
often in the 70–74 age group, 75% of cases are detected in men
older than 65, and 25% in men  above75 years.
Its incidence and early detection continues to increase due
especially to preventive administration of the prostatic spe-
ciﬁc antigen (PSA) and to population aging. More than 60% of
tumours are detected in stages I and II.
The fact that at present more  forms of prostate cancer are
being diagnosed more  often, and also the occurrence of ill-
ness in patients with a long life expectancy is substantially
changing approaches to treatment. Among curative treatment
methods of localized prostate cancer are radical prostatec-
tomy (RAPE), external radiotherapy, interstitial brachytherapy
(BRT), and “watchful waiting”. This last method is being used
more  frequently due to the detection of clinically insigniﬁ-
cant forms of the disease. It is, however, important to identify
patients who have, on the basis of the clinical and patholog-
ical characteristics of the tumour, a low possibility of disease
progression. Treatment strategy depends especially on the
evaluation of the aggressiveness of the tumour, comorbidity
and biological age. The approach to treatment of men  older
than 75 is not unequivocal.1 It is always imperative to care-
fully consider life expectancy respective to intercurrence and
the overall state of the patient.
Equal to radical prostatectomy is the possibility of curative
treatment with radical radiotherapy. Radical prostatectomy in
older men  is not often indicated, because it is connected with
a higher level of complications. A comparison of the com-
plications of radiotherapy and RAPE among older men  was
made by Canadian authors. A higher degree of complications
was found in the group treated surgically.2 There is another
work that conﬁrms that higher age is connected with larger
blood loss and higher incidence of further complications.3
The most frequent and unpleasant postoperative complica-
tion after radical prostatectomy is urinary incontinence and it
is precisely this which is much more  likely to occur after oper-
ation with older men.4 Evaluation of and work on continence
one year post-operation has been undertaken by Shikanova.5
The probability of incontinence among men  of 75 years was
the worst in comparison with those less than 70 and less
than 65 (0.59 vs. 0.63 vs. 0.66). Similar results were also pub-
lished after the use of laparoscopic RAPE in men  over 75
years. Once again, urinary incontinence was more frequent
than with younger men.6 Comparison of perioperative mor-
bidity in older men  who had undergone open RAPE with those
operated laparoscopically also showed a higher risk of hae-
morrhage and the appearance of urinary ﬁstulae with open
radical prostatectomy.7
The objective is then to ﬁnd the best way of choosing
patients for radical operation, for example on the basis of
evaluation of intercurrence.8
A further possible treatment modality with curative poten-
tial is radical radiotherapy, often used especially with older
patients. In the last two decades radiotherapy has made great
advances. The escalation of irradiation dosage has signiﬁ-
cantly added to the improvement in treatment outcomes in
localized prostate cancer, because it has been shown thatIschaemic heart disease 4
Hyperlipidaemia 4
prostate cancer is dosage-dependent: the higher the irra-
diation dosage applied, the better results achieved.9–11 The
dosage required to ensure control over the illness should be
greater than 72 Gy.12 The ability of conventional radiotherapy
to deliver such a dosage is limited by the high rate of gas-
trointestinal (GI) and genitourinary (GU) complications. For
this reason, in order to increase dosage to the required vol-
ume,  it is appropriate to use the new technologies of external
radiotherapy (e.g. conformal; 3D CRT or intensively modulated
radiotherapy: IMRT) or a combination of external radiotherapy
and brachytherapy.
Each of the aforementioned methods has its advantages,
disadvantages, limitations and indications. Rapid develop-
ment has also been achieved in the ﬁeld of brachytherapy
(BRT) which is now also obtainable conformally, which allows
for new planning systems and techniques implemented using
transrectal ultrasonography (TRUS, the guided technique). In
recent years, interstitial brachytherapy has been enjoying a
revival especially as a result of new technologies (ultrasound
navigation technology), which allows a more  precise calcula-
tion of the position of the source. With the use of conformal
brachytherapy, it is possible to achieve higher dosage in the
target volume even to over 100 Gy. The main advantage of a
combination of RT and HDR BRT, apart from dosage escala-
tion, might also be the overall reduction in treatment time of
2–3 weeks, when compared with external RT alone.
2. Materials  and  methods
In our cancer centre, from 2004 to 2010, we  treated 20 men
over the age of 75 with a combination of external radiothe-
rapy and HDR brachytherapy. At the start of the treatment,
the average age of the group was 76.9 years (75–79, median 77
years). Nine of the men  had prostate cancer with a high risk
of recurrence, 7 had cancer of intermediate risk and 4 had low
risk prostate cancer. Characteristics patients and tumours are
listed in Table 1. The majority of patients (70%) had less than
two comorbidities and the performance status of all was 0–1
according to WHO.  Among the most frequent intercurrence
was hypertension and ischaemic heart disease (Table 2).
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Table 3 – Treatment protocol for the external beam radiotherapy and brachytherapy combination.
Risk of recurrence 3D CRT BRT
Low risk group
T1a-T2a
+GS ≤ 6
+PSA ≤ 10
PTV  Prostate
+base of seminal vesicles
+safety margin
Prostate
+base  of seminal vesicles
+margin 3 mm
Technique 6 isocentric ﬁelds – conformal RT Interstitial temporary
implantation
Dose 45 Gy in 25 fractions
5 fractions/week
2  ×8 Gy
(in 3rd and 5th week of 3D CRT)
Intermediate risk group
T2b
or GS = 7
or PSA 10–20
PTV Prostate
+seminal vesicles
+safety margin
Prostate
+base  of seminal vesicles
+margin 3 mm
Technique 6 isocentric ﬁelds – conformal RT Interstitial temporary
implantation
Dose 50.4 Gy in 28 fractions
5 fractions/week
2  × 8 Gy
(in 3rd and 5th week of 3D CRT)
High risk group
GS > 7
or PSA > 20
or T2c
PTV  Pelvis Prostate
+base of seminal vesicles
+margin 3 mm
Technique Box Interstitial temporary
implantation
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All men  underwent external radiotherapy in the pelvic
egion (in the patient group with high recurrence risk) in dose
5.0–50.4 Gy in 25–28 fractions or external irradiation of the
rostate and parts of the seminal vesicles (intermediate and
ow risk) in dose 45.0 Gy in 25 fractions. External radiotherapy
as supplemented with HDR brachytherapy in two fractions
n dose 8.0 Gy per fraction, the interval between fractions was
wo weeks. HDR brachytherapy was conducted in the 3rd and
th weeks of external RT. Treatment protocol is described in
able 3. On the day preceding brachytherapy, the patients were
dmitted to the department, where preparations were made
hich included introduction of a permanent urinary catheter.
DR BRT was performed under spinal anaesthesia, needles
ere applied to the prostate transperineally under the control
f transrectal sonography. The operation time was between
20 and 150 min. The day after the surgery, the catheter was
xtracted and the patient was released and on the same day
xternal radiation continued.
Hormonal treatment was added in the high risk group (four
onths before radiotherapy and concomitantly with RT total
ndrogen deprivation and two years after RT bicalutamide
lone). In patients with medium risk tumours hormonal treat-
ent consisted of total androgen deprivation two months
efore and concomitantly with RT.
.  Results
he average observation period for our group was 50 months
10–80), and the median 57 months.We  evaluated perioperative, acute post-radiation and late
ost-radiation toxicity according to the RTOG criteria. No peri-
perative complications occurred, all men  endured more  than
wo-hours of surgery under spinal anaesthesia without any fractions
eek
2  × 8 Gy
(in 3rd and 5th week of 3D CRT)
difﬁculties. After needle extraction from the perineum, bleed-
ing was minimal. The second day after surgery, the urinary
catheter was removed and all patients were able to urinate
naturally. Acute genitourinary toxicity (GU) occurred in 12
(60%), of whom 10 at G1 and two at G2. Most common was
frequent urination and nycturia. Acute gastrointestinal toxic-
ity (GIT), most frequently in the form of frequent stools and
tenesmus, was recorded in 5 men  (25%), but only at grade 1.
Late GU toxicity, or that longer than 6 months, was observed in
7 patients (35%) (one patient at grade 3 and the others at grade
1), late GIT toxicity was recorded only in 3 patients (15%) (grade
1). Toxicity of radiotherapy is described in Table 4.
Fourteen men (70%) lived post treatment longer than 3
years, 10 (50%) longer than 5 years. During the observation
period, only one patient died after 2 years of heart failure and
only in one did the illness show progression, from which he
died after 53 months.
Long-term biochemical remission was achieved in 18
patients (90%), in two patients there was biochemical failure
(one died from progression of illness, the other from heart
failure).
4.  Discussion
As already stated, it is not clear which treatment option
to choose in older men  with localized prostate cancer. The
recommendation of the International Society of Geriatric
Oncology (ISGO) speaks of an individual approach, which is
based mainly on the judgement of further additional diseases
and the overall state of the patient, and not merely on the indi-
cations of eventual therapy according to chronological age.
Patients should be classiﬁed into 4 groups: (1) the “healthy”
patient, without uncontainable comorbidity, fully capable
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Table 4 – Toxicity of radiotherapy.
Toxicity Grade 1 (No of pts.) Grade 2 (No of pts.) Grade 3 (No of pts.)
Acute GU 10 2 –
Acute GIT 5 – –
Late GU 6 
Late GIT 3 
of daily activities, without malnutrition. He should receive
the same treatment as a younger man; (2) the “vulnerable”
patient, who should receive standard treatment after med-
ical intervention; (3) the “frail” patient, who should receive
adaptive treatment; (4) the very ill patient, who should receive
symptomatic treatment.13 Patients from our group should be
incorporated into group 1, and maximally into group 2.
According to various population databases, treatment of
older men  tends to be more  active, especially in patients with
intermediate or high-risk prostate cancer.14 It seems that nei-
ther further nor multiple comorbidity is taken into account.
The choice of treatment used on patients with prostate can-
cer both younger and older than 75 years was the subject
of a study undertaken with the multi-institutional database
CapSURE.15
Well-selected older patients with higher-risk tumours
and without serious comorbidities undoubtedly beneﬁt from
radical treatment when compared with watchful waiting.
Conversely, older patients with lower-risk carcinoma should
beneﬁt rather from observation. Similar views were expressed
in another study which concerned the quality of life.16 In
lower-risk carcinomas in older men, watchful waiting is appro-
priate as an alternative to active treatment. Nevertheless,
individual preferences are always a decisive factor. Unfortu-
nately, we always encounter the application of a stand-alone
hormonal antiandrogen therapy in older men  with prostate
cancer without serious intercurrence. This palliative approach
may cause a contrary effect of shortening life expectancy and
worsening the quality of life. The risk of cardiovascular death
in hormonal treatment lasting more  than one year is up to
20% higher.17 Androgen deprivation especially in low risk car-
cinoma may in fact decrease overall survival.
A meta-analysis of data from the current year from 4 major
RTOG studies was undertaken to compare treatment results in
men  under and over 70 years with local advanced prostate
cancer who  had been treated by radiotherapy in combina-
tion with hormonal treatment. Overall survival was lower in
the group of older men  (10-year overall survival 55% vs. 41%,
p < 0.0001), higher was death from other causes and lower
prostate-speciﬁc mortality; also lower was the occurrence of
distant metastases.18 A possible cause might have been the
lower aggression of the tumours in the higher age group. Our
patients in the group of intermediate and high risk were also
treated with a combination of hormonal treatment and radio-
therapy. A worsened tolerance to the hormonal treatment
was not recorded. Only one man, who had been treated with
antiandrogens after progression, died from cardiovascular dis-
ease which was already present in anamnesis before the start
of the treatment (myocardial infarction).Alibhai has questioned the beneﬁt of curative treatment
in older men.19 Age should not be a hindrance to treatment
especially in men  with little comorbidity and moderately or– 1
– –
poorly differentiated carcinoma. Only one patient in our group
died from associated diseases (median of observation in our
group was almost 5 years). Therefore, if we  had not chosen
an active approach to treatment, patients with a risk of carci-
noma would most likely have experienced a progression of the
disease. Our patients had in 80% of cases an intermediate or
high risk carcinoma. The remaining four men  (20%) with low
cancer risk preferred active treatment before the observation.
HDR brachytherapy has been in use for some decades in
the treatment of prostate cancers but the studies relating to
this form of treatment in men  over 75 have not been much
published. Chenov’s work evaluating morbidity of brachyther-
apy and its relationship with age showed a higher urinary
(obstruction, incontinence, bleeding, ﬁstulae) and even a
higher intestinal morbidity (proctitis, bleeding) in men over
65.20 Among other risk factors apart from age are intercur-
rences. In our study for HDR brachytherapy our patients were
chosen appropriately. None of them had either perioperative
complications or acute higher or later toxicity. Genitourinary
toxicity was exceptionally grade 1 and only once was later GU
recorded at a toxicity of grade 3, which manifested itself as
bladder retention with the importance of the installation of
a permanent urinary catheter. Thirteen of our patients (65%)
had hypertension, 4 (20%) currently also have ischaemic heart
disease. It is apparent that compensated chronic intercurrent
illnesses such as ischaemic heart disease and hypertension do
not worsen tolerance to HDR brachytherapy.
5.  Conclusions
In spite of the low number of patients, we  can state that the
tolerance to the treatment was very good, toxicity low, and the
survival of patients long, despite their advanced age.
In addition, using HDR BRT resulted in a shortened overall
treatment period of up to 2 weeks without greater complica-
tions and without further inﬂuence on the quality of life.
HDR BRT is possible and well tolerated in men  in good
condition over 75 years of age and without serious intercur-
rence. Well-selected older patients with higher-risk tumours
and without serious comorbidities undoubtedly beneﬁt from
radical treatment when compared with watchful waiting.
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